Testing effectiveness (Phase 2)Study completedNCT01997333
What this trial is testing
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Who this might be right for
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Celldex Therapeutics 327